Open Access
CC BY-NC-ND 4.0 · Laryngorhinootologie 2022; 101(S 02): S202
DOI: 10.1055/s-0042-1746637
Abstracts | DGHNOKHC
Head-Neck-Oncology: Clinical studies

Therapy of advanced head and neck cancer with double checkpoint blockade followed by radioimmunotherapy – results of the CheckRad-CD8 study.

Authors

  • Antoniu-Oreste Gostian

    1   Universitätsklinikum Erlangen, HNO, Kopf- und Halschirurgie Erlangen

  • Markus Eckstein

    2   Universitätsklinikum Erlangen, Pathologisches Institut Erlangen

  • Sandra Rutzner

    3   Universitätsklinikum Erlangen, Klinik für Strahlentherapie Erlangen

  • Jens von der Grün

    4   Universitätsklinikum Frankfurt, Zentrum der Radiologie – Klinik für Strahlen- therapie und Onkologie Frankfurt/Main

  • Thomas Illmer

    5   Gemeinschaftspraxis Hämatologie – Onkologie, Freiberg- Richter- Jacobasch – Illmer – Wolf Dresden

  • Matthias G. Hautmann

    6   Universitätsklinikum Regensburg, Klinik und Poliklinik für StrahlentherapieRegensburg

  • Thomas B. Brunner

    7   Universitätsklinikum Magdeburg, Universitätsklinik für Strahlentherapie Magdeburg

  • Simon Laban

    8   Universitätsklinikum Ulm, Hals- Nasen- und Ohrenheilkunde Ulm

  • Gunther Klautke

    9   Klinikum Chemnitz, Klinik für Radioonkologie Chemnitz

  • Balint Tamaskovics

    10   Universitätsklinikum Düsseldorf, Klinik für Strahlentherapie und Radioonkologie Düsseldorf

  • Benjamin Frey

    3   Universitätsklinikum Erlangen, Klinik für Strahlentherapie Erlangen

  • Arndt Hartmann

    2   Universitätsklinikum Erlangen, Pathologisches Institut Erlangen

  • Wilfried Budach

    10   Universitätsklinikum Düsseldorf, Klinik für Strahlentherapie und Radioonkologie Düsseldorf

  • Udo Gaipl

    3   Universitätsklinikum Erlangen, Klinik für Strahlentherapie Erlangen

  • Heinrich Iro

    1   Universitätsklinikum Erlangen, HNO, Kopf- und Halschirurgie Erlangen

  • Rainer Fietkau

    3   Universitätsklinikum Erlangen, Klinik für Strahlentherapie Erlangen

  • Markus Hecht

    3   Universitätsklinikum Erlangen, Klinik für Strahlentherapie Erlangen
Weitere Informationen
Auch verfügbar auf
 
 

    Introduction The CheckRad-CD8 study investigates the feasibility and efficacy of chemo-immune induction therapy followed by radioimmunotherapy with double immune checkpoint blockade after prior patient selection based on intratumoral CD8 cells.

    Patients and Methods This multicenter phase II study treated patients with stage III-IVB head and neck tumors with a single cycle of cisplatin, docetaxel, durvalumab, and tremelimumab. Patients with increased CD8+ immune cell density or pathologic complete response (pCR) received radioimmunotherapy and another three cycles of durvalumab/tremelimumab followed by eight cycles of durvalumab mono.

    Results Between September 2018 and May 2020, 80 patients were enrolled. The median follow-up time is 17.2 months. After induction chemoimmunotherapy, 41 patients had pCR, and another 31 had an increase in CD8+ cells. Radioimmunotherapy achieved a feasibility rate of 82%: of 60 patients, 10 experienced dose-limiting toxicity, and 4 others discontinued treatment. The cohort of patients after radioimmunotherapy had progression-free survival rates of 78% (CI(95% confidence interval) 69-90%) and 72% (CI 61-85%) at one and two years, respectively, and overall survival rates of 90% (CI 83-98%) and 84% (CI 74-94%). Grade 3-4 toxicities included predominantly dysphagia (53%), leukopenia (52%), and infection (32%). CONCLUSION: The study met its primary endpoint of feasibility of radioimmunotherapy. Induction chemoimmunotherapy followed by chemotherapy-free radioimmunotherapy after intratumoral CD8+ immune cell-based patient selection achieved a promising oncologic outcome.


     

    Conflict of Interest

    The author declares that there is no conflict of interest.

    Publikationsverlauf

    Artikel online veröffentlicht:
    24. Mai 2022

    © 2022. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/).

    Georg Thieme Verlag
    Rüdigerstraße 14, 70469 Stuttgart, Germany